Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy
Authors
Keywords
-
Journal
Nature Communications
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-04-23
DOI
10.1038/s41467-021-22407-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tracing tumorigenesis in a solid tumor model at single-cell resolution
- (2020) Samantha D. Praktiknjo et al. Nature Communications
- The Future of Immunotherapy-Based Combination Therapy in Metastatic Renal Cell Carcinoma
- (2020) Rohan Garje et al. Cancers
- IOX1 Suppresses Wnt Target Gene Transcription and Colorectal Cancer Tumorigenesis through Inhibition of KDM3 Histone Demethylases
- (2020) Rosalie G. Hoyle et al. MOLECULAR CANCER THERAPEUTICS
- Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
- (2019) Xianjie Jiang et al. Molecular Cancer
- Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
- (2019) Jérôme Galon et al. NATURE REVIEWS DRUG DISCOVERY
- A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer
- (2019) Jose M. Pacheco et al. Frontiers in Oncology
- Tumor Microenvironment‐Triggered Aggregated Magnetic Nanoparticles for Reinforced Image‐Guided Immunogenic Chemotherapy
- (2019) Qinjun Chen et al. Advanced Science
- Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice
- (2019) Wenwen Yue et al. Nature Communications
- PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
- (2019) Yilun Wu et al. Frontiers in Immunology
- Photothermal-Chemotherapy Integrated Nanoparticles with Tumor Microenvironment Response Enhanced the Induction of Immunogenic Cell Death for Colorectal Cancer Efficient Treatment
- (2019) Yayu Wen et al. ACS Applied Materials & Interfaces
- Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells
- (2019) Mengyun Ke et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Screening of kinase inhibitors downregulating PD-L1 expression via on/in cell quantitative immunoblots.
- (2019) Yongli Xie et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- KYA1797K down-regulates PD-L1 in colon cancer stem cells to block immune evasion by suppressing the β-catenin/STT3 signaling pathway
- (2019) Zhiyan Ruan et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Laser Immunotherapy in Combination with Perdurable PD-1 Blocking for Treatment of Metastatic Tumor
- (2018) Lihua Luo et al. ACS Nano
- Regulation and Function of the PD-L1 Checkpoint
- (2018) Chong Sun et al. IMMUNITY
- Histone demethylase JMJD1A promotes colorectal cancer growth and metastasis by enhancing Wnt/β-catenin signaling
- (2018) Kesong Peng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chemotherapy induces enrichment of CD47+/CD73+/PDL1+immune evasive triple-negative breast cancer cells
- (2018) Debangshu Samanta et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Recent advances in small molecule based cancer immunotherapy
- (2018) Binbin Cheng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules
- (2018) Jeffrey Yang et al. MEDICINAL RESEARCH REVIEWS
- Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1
- (2018) Jong-Ho Cha et al. MOLECULAR CELL
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficient PD-L1 gene silence promoted by hyaluronidase for cancer immunotherapy
- (2018) Xiuwen Guan et al. JOURNAL OF CONTROLLED RELEASE
- Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms
- (2017) Danae A Delivanis et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- KDM3 epigenetically controls tumorigenic potentials of human colorectal cancer stem cells through Wnt/β-catenin signalling
- (2017) Jiong Li et al. Nature Communications
- HDAC inhibition potentiates immunotherapy in triple negative breast cancer
- (2017) Manuela Terranova-Barberio et al. Oncotarget
- Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells
- (2017) Rachel M. Gibbons Johnson et al. Frontiers in Immunology
- Low dose cyclophosphamide: Mechanisms of T cell modulation
- (2016) Mutsa Tatenda Madondo et al. CANCER TREATMENT REVIEWS
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
- (2016) Christina Pfirschke et al. IMMUNITY
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
- (2016) Axel Hoos NATURE REVIEWS DRUG DISCOVERY
- Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
- (2016) R. D. Dorand et al. SCIENCE
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy
- (2015) Samuel G. Awuah et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging
- (2015) Roy L. Maute et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models
- (2015) Jonathan Rios-Doria et al. NEOPLASIA
- A Cell-Permeable Ester Derivative of the JmjC Histone Demethylase Inhibitor IOX1
- (2014) Rachel Schiller et al. ChemMedChem
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
- (2014) Antonella Sistigu et al. NATURE MEDICINE
- Inhibition of Wnt/β-catenin signaling downregulates P-glycoprotein and reverses multi-drug resistance of cholangiocarcinoma
- (2013) Dong-Yan Shen et al. CANCER SCIENCE
- CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
- (2013) P. A. Ott et al. CLINICAL CANCER RESEARCH
- Pan-Histone Demethylase Inhibitors Simultaneously Targeting Jumonji C and Lysine-Specific Demethylases Display High Anticancer Activities
- (2013) Dante Rotili et al. JOURNAL OF MEDICINAL CHEMISTRY
- Inhibition of the mevalonate pathway to override chemoresistance and promote the immunogenic demise of cancer cells
- (2013) Chiara Riganti et al. OncoImmunology
- A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death
- (2012) Abhishek D Garg et al. EMBO JOURNAL
- Doxil® — The first FDA-approved nano-drug: Lessons learned
- (2012) Yechezkel (Chezy) Barenholz JOURNAL OF CONTROLLED RELEASE
- The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G1/S transition in cancer cells via transcriptional regulation of the HOXA1 gene
- (2011) Hyun-Soo Cho et al. INTERNATIONAL JOURNAL OF CANCER
- B7-H1 Expressed by Activated CD8 T Cells Is Essential for Their Survival
- (2011) V. Pulko et al. JOURNAL OF IMMUNOLOGY
- Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
- (2011) M. Michaud et al. SCIENCE
- Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation
- (2009) Abhishek D. Garg et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death
- (2009) Theocharis Panaretakis et al. EMBO JOURNAL
- Immunogenic death of colon cancer cells treated with oxaliplatin
- (2009) A Tesniere et al. ONCOGENE
- Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways
- (2008) Brian T. Fife et al. IMMUNOLOGICAL REVIEWS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now